<DOC>
	<DOCNO>NCT01136252</DOCNO>
	<brief_summary>Adalimumab humanize recombinant monoclonal antibody fragment target tumor necrosis factor . This study ass safety efficacy intravitreal adalimumab administer patient choroidal neovascularization secondary age-related macular degeneration non-responders conventional treatment intravitreal ranibizumab .</brief_summary>
	<brief_title>Intravitreal Adalimumab Patients With Choroidal Neovascularization Secondary Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Choroidal neovascularization secondary agerelated macular degeneration nonresponders conventional treatment ranibizumab ( active choroidal neovascularization load phase one injection per month three consecutive month , follow maintenance phase 5 injection last 12 month 3 injection last 6 month Only one functional eye Hypersensitivity adalimumab component formulation Previous systemic treatment adalimumab Cancer Life expectancy &lt; 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>